Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy

Annals of Surgery

Volumn 257, Issue 1, 2013, Pages 114-120

  Goéré, Diane ^a   Benhaim, Léonor ^a   Bonnet, Stéphane ^a   Malka, David ^a   Faron, Matthieu ^a   Elias, Dominique ^a   Lefèvre, Jérémie H ^a   Deschamps, Frédéric ^a   Dromain, Clarisse ^a   Boige, Valérie ^a   Dumont, Frédéric ^a   De Baere, Thierry ^a   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adjuvant chemotherapy; colorectal cancer; hepatic arterial infusion; liver metastases

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84871596728     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31827b9005     Document Type: Article

References (55)

1. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management ofliver metastases from colorectal cancer. Ann Surg. 2006;244:254-259. (Pubitemid 44305540)
2. Leporrier J, Maurel J, Chiche L, et al. A population-based study of the in-cidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465-474.
3. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastaticcolorectalcancer:apopulation-basedstudy. Cancer. 2007;109:718-726.
4. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241-1246.
5. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival follow-ing liverresectionforhepatic colorectalmetastases. Ann Surg. 2002;235:759-766. (Pubitemid 34547293)
6. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br JCancer. 2006;94:982-999.
7. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised con-trolled trial. Lancet. 2008;371:1007-1016. (Pubitemid 351392040)
8. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection ofmetastases from colorectal cancer: a pooled analysis of tworandomizedtrials. JClin Oncol. 2008;26:4906-4911.
9. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial ofadjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976-4982. (Pubitemid 46631399)
10. Langer B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus leucovorin (I-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol. 2002;21:149a. Ab-stract 592.
11. Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204:753-761. (Pubitemid 46661187)
12. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-946. (Pubitemid 27106275)
13. Nakajima Y, Nagao M, Ko S, et al. Clinical predictors ofrecurrence site after hepatectomy for metastatic colorectal cancer. Hepatogastroenterology. 2001;48:1680-1684. (Pubitemid 34003503)
14. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evalu-ation of the treatment ofcolorectal cancer metastatic to the liver. J Clin Oncol. 1990;8:1885-1893. (Pubitemid 20382353)
15. Lygidakis NJ, Ziras N, Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology. 1995;42:155-161.
16. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery vs. surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases ofcolorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen).Ann Surg. 1998;228:756-762. (Pubitemid 30191686)
17. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterialinfusionofchemother- apy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039-2048. (Pubitemid 30035952)
18. Rudroff C, Altendorf-Hoffmann A, Stangl R, et al. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resec-tion of colorectal liver metastases. Langenbecks Arch Surg. 1999;384: 243-249. (Pubitemid 29309067)
19. Tono T, Hasuike Y, Ohzato H, et al. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resec-tion of colorectal liver metastases: a randomized study. Cancer. 2000;88: 1549-1556. (Pubitemid 30183139)
20. Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease ofcol-orectal origin: the value oflocoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective ran-domized study. Hepatogastroenterology. 2001;48:1685-1691. (Pubitemid 34003504)
21. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for re-sectable metastatic colorectal carcinoma to the liver: surgical resection ofhep-atic metastases in combination with continuous infusion ofchemotherapy\-an intergroup study. J Clin Oncol. 2002;20:1499-1505. (Pubitemid 34260528)
22. Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev. 2006;4:CD003770.
23. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;77:1254-1562.
24. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepaticresectionformetastatic colorectalcancer: analysisof1001 consecutive cases. Ann Surg. 1999;230:309-318.
25. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291-299. (Pubitemid 29408866)
26. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metas-tases: value forrisk scoring systems? Ann Surg. 2007;246:183-191. (Pubitemid 47196514)
27. Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007;246:806-814. (Pubitemid 350035657)
28. Rees M, Tekkis PP, Welsh FK, et al. Evaluation oflong-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-135.
29. Sobin LH, Wittekind Ch. TNMClassification of Malignant Tumours. Hoboken, NJ: John Wiley & Sons; 2002.
30. Deschamps F, Rao P, Teriitehau C, et al. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and pre-dictive factors oflong-term functionality J Vasc Interv Radiol. 2010;21:1681-1688.
31. Elias D, Goere D, Boige V, et al. Outcome ofposthepatectomy-missing col-orectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol. 2007;14:3188-3194. (Pubitemid 47594272)
32. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23:4881-4887. (Pubitemid 46223993)
33. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Available at: http://evs.nci. nih.gov/ftp1/CTCAE/.
34. Gregoire E, Hoti E, Gorden DL, et al. Utility or futility of prognostic scor-ing systems for colorectal liver metastases in an era of advanced multimodal therapy Eur J Surg Oncol. 2010;36:568-574.
35. Smith MD, Mc Call JL. Systematicreviewoftumournumberandoutcomeafter radicaltreatmentof colorectallivermetastases. Br J Surg.2009;96:1101-1113.
36. Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy formul-tiple (four or more) colorectal metastases in the era of effective chemotherapy Ann Surg Oncol. 2007;14:1151-1160.
37. Voest EE, Snoeren N, Schouten SB, etal.Arandomized two-armphase IIIstudy to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. J Clin Oncol. 2011;29:(suppl). Abstract 3565.
38. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing beva-cizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11-16.
39. De Gramont A, Van Cutsem E, Tabernero J, et al. AVANT: results from a ran-domized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treat-ment for colon cancer. J Clin Oncol. 2011;29(suppl4). Abstract362.
40. Kemeny NE, Jarnagin WR, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or with-out bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol. 2011;29:884-889.
41. Falcone A, Ricci S, Brunetti I, et al. Phase III trial ofinfusional fluorouracil, leucovorin, oxaliplatin, andirinotecan(FOLFOXIRI) comparedwithinfusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-1676. (Pubitemid 46797946)
42. Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/ leucovorin, irinotecanandoxaliplatin (FOLFIRINOX): aphase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62:195-201. (Pubitemid 351692073)
43. Chang AE, Schneider PD, Sugarbaker PH, etal.Aprospectiver andomized trial ofregional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685-693. (Pubitemid 18056182)
44. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107:459-465. (Pubitemid 17149758)
45. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7:1646-1654. (Pubitemid 19272834)
46. Martin JK, Jr, O'Connell MJ, Wieand HS, et al. Intra- arterialfloxuridinevssys-temic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.Arch Surg. 1990;125:1022-1027. (Pubitemid 20249340)
47. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion offlox-uridine in patients with liver metastases from colorectal carcinoma: long-term results of aprospectiverandomizedcontroltrial. J Clin Oncol. 1992;10:1112-1118.
48. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255-1260. (Pubitemid 24334681)
49. Lorenz M, Müller HH. Randomized, multicenter trial offluorouracil plus leu-covorin administered either via hepatic arterial or intravenous infusion ver-sus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243-254. (Pubitemid 30056411)
50. Kerr DJ, Mc Ardle CS, Ledermann J, et al. Medical Research Council'scolorec-tal cancer study group; European Organisation for Research and Treatment of Cancer colorectal cancer study group. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361:368-373. (Pubitemid 36164968)
51. Kemeny NE, Niedzwiecki D, Hollis D, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial ofefficacy quality oflife, andmolecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395-1403. (Pubitemid 46622004)
52. Kern W, Beckert B, Lang N, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol. 2001;12:599-603. (Pubitemid 32519910)
53. Goéré D, Deshaies I, de Baere T, et al. Prolonged survival of initially un-resectable hepatic colorectal cancer patients treated with hepatic arterial in-fusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251:686-691.
54. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durabil-ity of hepatic artery infusion pumps for unresectable colorectal liver metas-tases: an institutional experience of544 consecutive cases. J Am Coll Surg. 2005;201:57-65. (Pubitemid 40840564)
55. Tanaka K, Shimada H, Ueda M, et al. Role of hepatectomy in treating multiple bilobar colorectal cancer metastases. Surgery. 2008;143:259-270.